Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Intrinsic Value: Projected FCF is $0.11 as of Aug. 02, 2026, which is 99% below its 10-year median of 7.38. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 402 Medical Devices & Instruments companies, NIOX Group ranks worse than 93.53% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-02), NIOX Group's Intrinsic Value: Projected FCF is $0.11. The stock price of NIOX Group is $0.82. Therefore, NIOX Group's Price-to-Intrinsic-Value-Projected-FCF of today is 7.5.
The historical rank and industry rank for NIOX Group's Intrinsic Value: Projected FCF or its related term are showing as below:
CSSPF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 6.82 Med: 7.38 Max: 7.45
Current: 7.45
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of NIOX Group was 7.45. The lowest was 6.82. And the median was 7.38.
CSSPF's Price-to-Projected-FCF is ranked worse than 93.53% of 402
companies
in the Medical Devices & Instruments industry
Industry Median: 1.48
vs CSSPF: 7.45
NIOX Group (OTCPK:CSSPF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
NIOX Group's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.82
/
0.11684832136236
=
7.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group Intrinsic Value: Projected FCF Related Terms
NIOX Group Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for NIOX Group's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, NIOX Group's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where NIOX Group's Price-to-Projected-FCF falls into.
NIOX Group Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.11 mean?
NIOX Group (CSSPF) has a Intrinsic Value: Projected FCF of $0.11 as of Aug. 02, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on NIOX Group and its competitors. This is 99% below median its historical median of 7.38. Over the past decade, NIOX Group's Intrinsic Value: Projected FCF has ranged from 6.82 to 7.45. According to the industry distribution chart, NIOX Group ranks #376 out of 402 companies in the Medical Devices & Instruments industry, placing it in the top 93.5%.
Is NIOX Group's Intrinsic Value: Projected FCF too high?
NIOX Group's current Intrinsic Value: Projected FCF of $0.11 is 99% below median its 10-year median of 7.38. Over the past 10 years, this metric has ranged from a low of 6.82 to a high of 7.45. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.48. NIOX Group's value of $0.11 is 92.6% below this industry median. Based on the distribution chart, NIOX Group ranks #376 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Intrinsic Value: Projected FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #376 out of 402 companies for Intrinsic Value: Projected FCF. This places NIOX Group in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.48. NIOX Group's value of $0.11 is 92.6% below this benchmark. Historically, NIOX Group's own Intrinsic Value: Projected FCF has ranged from 6.82 to 7.45 over the past decade. While the company's 10-year median is 7.38 vs. the industry median of 1.48, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.48, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Intrinsic Value: Projected FCF of $0.11 is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Intrinsic Value: Projected FCF is $0.11, which is 99% below median its own 10-year median of 7.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.82 — trading 32.2% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.11, which is 99% below median its 10-year median of 7.38 and 92.6% below the Medical Devices & Instruments industry median of 1.48. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Intrinsic Value: Projected FCF is $0.11 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.2% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Intrinsic Value: Projected FCF: $0.11 (99% below median its 10-year median of 7.38)
GF Value™: $1.21 vs. price of $0.82 (32.2% below fair value)
Industry Position: 92.6% below the Medical Devices & Instruments median (#376 of 402)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
